ArticleCNS neuroscience & therapeutics2026
Choroid Plexus Abnormalities in Autoimmune Encephalitis.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundRecent evidence suggests that the choroid plexus (ChP) serves as a gateway for neuroinflammation. Autoimmune encephalitis (AE) features a high inflammatory burden, yet the role of ChP in AE remains unclear. This study compared choroid plexus volume (CPV) at symptom onset between AE patients and healthy controls (HCs), and evaluated its association with prognosis.
methodsThis single-center study included 151 AE patients with definite autoantibodies. ChP volume (CPV) was segmented from baseline 3D-T1 MRI and normalized. Baseline CPV was compared between AE and age- and sex-matched HCs, and its associations with 12-month functional outcomes (mRS) and progression to autoimmune encephalitis-associated epilepsy (AEAE) were assessed. A logistic regression model based on ChP radiomic features was developed to predict AEAE. Exploratory cerebrospinal fluid (CSF) proteomics and metabolomics were performed in a small subset to generate hypotheses on underlying pathways.
resultsOf 151 AE patients, 141 completed 12-month follow-up; 26 (18.4%) developed AEAE. AE patients had significantly larger CPV than controls (1.235 ± 0.274 vs. 1.035 ± 0.264, p < 0.001). Larger baseline CPV was significantly associated with AEAE and mRS (p < 0.05). A two-feature radiomic model (RunEntropy and original volume) predicted AEAE with AUCs of 0.766 (training) and 0.851 (test). Exploratory proteomics in a subset suggested CPV-correlated downregulation of glutamatergic synapse pathways and upregulation of PI3K-Akt/integrin pathways.
conclusionsBaseline CPV was greater in AE patients than in HCs, and larger baseline CPV was associated with progression to AEAE and poor one-year functional outcomes. ChP imaging may aid in early risk stratification for AE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.